# Zevra Therapeutics, Inc. (ZVRA) Stock Analysis: A 192% Potential Upside in Rare Disease Treatment

- Link: https://www.directorstalkinterviews.com/zevra-therapeutics-inc-zvra-stock-analysis-a-192-potential-upside-in-rare-disease-treatment/4121216952
- Published: 2025-09-19T10:47:11+01:00
- Author: Madison Wilson

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) is making waves in the biotechnology sector
with its promising portfolio aimed at addressing unmet medical needs for rare diseases.
Headquartered in Celebration, Florida, Zevra is strategically positioned within 
the healthcare sector, standing out with a market capitalization of approximately
$445.71 million.

The company’s stock is currently priced at $7.94, reflecting a modest price change
of 0.61% within its 52-week range of $6.56 to $12.79. Despite the current price 
being below its 200-day moving average of $8.71, the stock presents significant 
growth potential. Analysts have set a bullish average target price of $23.22, suggesting
a staggering potential upside of 192.46%.

Zevra’s valuation metrics present a mixed picture. The absence of a trailing P/E
ratio and PEG ratio indicates that the company is not yet profitable, which is common
for biotech firms in the developmental stage. However, the forward P/E ratio of 
13.93 suggests that earnings are expected to improve, driven by robust revenue growth.

In terms of performance, Zevra reported an impressive revenue growth of 481.70%,
highlighting its strong operational momentum. Nevertheless, the company posted an
EPS of -0.25, underscoring ongoing challenges in turning revenue into profit. The
return on equity stands at 3.53%, indicating that while the company is utilizing
its equity efficiently, there’s room for improvement.

Zevra’s pipeline is particularly compelling. The company’s lead product candidate,
KP1077, is currently in clinical trials for idiopathic hypersomnia and narcolepsy,
conditions with significant unmet medical needs. Additionally, Zevra is advancing
Celiprolol in Phase 3 trials for vascular Ehlers Danlos syndrome, further solidifying
its focus on rare diseases. The commercial success of AZSTARYS for ADHD and the 
promising potential of OLPRUVA and MIPLYFFA for rare disorders underscore the company’s
diversified approach to addressing niche markets.

From a technical perspective, Zevra’s stock shows a relative strength index (RSI)
of 55.24, indicating neither overbought nor oversold conditions, while the MACD 
of -0.71 and a signal line of -0.65 suggest a bearish sentiment in the short term.
However, with eight buy ratings and no hold or sell recommendations, analyst sentiment
remains overwhelmingly positive.

Zevra’s strategic collaborations, such as those with Commave Therapeutics SA and
Acer and Relief Therapeutics, Inc., provide additional avenues for growth and innovation.
These partnerships not only enhance research and development capabilities but also
expand commercialization efforts, particularly for products like OLPRUVA.

As the company continues to navigate the complexities of drug development and commercialization,
investors should closely monitor its clinical trial milestones and regulatory updates.
Zevra’s focus on rare diseases, coupled with its promising pipeline and strong analyst
support, make it a noteworthy contender for investors seeking exposure in the biotech
space.

For those willing to embrace the inherent risks of biotech investments, Zevra Therapeutics
offers a compelling opportunity to capitalize on its potential upside and transformative
impact on rare disease treatment.

Share on: